Market news

Elanco Animal Health (NYSE:ELAN) President and CEO Jeff Simmons outlined the company’s growth strategy, product launches, deleveraging plans and outlook for its pet health and farm animal businesses during the Bank of America Healthcare Conference in London. Simmons said Elanco delivered 10% report

Elanco Animal Health Incorporated (NYSE: ELAN) will attend the BofA Securities Global Healthcare Conference 2026 on September 22, 2026. Jeff Simmons, president and CEO, will participate in a fireside chat on Tuesday, September 22 at 2:10 p.m. BST (9:10 a.m. EDT).

Elanco Animal Health (ELAN) drew fresh attention after its latest closing price of US$23.17. This put recent share moves and the company’s improving annual revenue and net income figures in sharper focus for investors. Recent moves show mixed momentum for Elanco Animal Health, with a 1-day share price return of 1.36% but a 7-day share price return down 5.43%. However, the 1-year total shareholder return of 24.30% and 3-year total shareholder return of 96.36% point to a much stronger...

Elanco Animal Health Incorporated (NYSE: ELAN) will announce its third quarter 2026 financial results on Friday, November 6, 2026. Elanco will also conduct a conference call on that day with the investment community and media to further detail the company's performance.

Elanco Animal Health Incorporated (NYSE: ELAN) will attend the Morgan Stanley 24th Annual Global Healthcare Conference on September 15, 2026. Jeff Simmons, president and CEO, Bob VanHimbergen, executive vice president and CFO, and Bobby Modi, executive vice president U.S. Pet Health and Global Digital Transformation will participate in a fireside chat on Tuesday, September 15 at 2:35 p.m. ET.

Purchasing 40,000 shares is a bullish signal for shareholders.

The completed 25,000-square-foot Elwood site expansion bolsters 's monoclonal antibody (mAb) production; supports delivery of next-generation pipelineINDIANAPOLIS, IN / ACCESS Newswire / August 31, 2026 / Animal Health Incorporated (NYSE:ELAN) announced the on-time completion of a 25,000-square-foot manufacturing expansion of its Elwood, Kansas manufacturing site. As one of only two animal health companies with mAb solutions on the market today, the expansion further strengthens 's leadership in

Detailed price information for Elanco Animal Health Inc (ELAN-N) from The Globe and Mail including charting and trades.

Insider buys into strength as the Elanco stock price has outperformed the S&P 500 over the last 12 months.

Elanco’s results for the second quarter were positively received by the market, reflecting momentum across both its Pet Health and Farm Animal businesses. Management attributed growth to strong execution in the U.S. and international markets, particularly the success of new products like Zenrelia and Credelio Quattro. CEO Jeffrey Simmons noted that “Zenrelia was the largest contributor to second quarter total Elanco growth,” with broad-based gains from innovative treatments and share gains in co

Detailed price information for Acadia Pharmaceutica (ACAD-Q) from The Globe and Mail including charting and trades.

Detailed price information for Costco Wholesale (COST-Q) from The Globe and Mail including charting and trades.

Detailed price information for Elanco Animal Health Inc (ELAN-N) from The Globe and Mail including charting and trades.

Vigilance and early intervention are key to minimizing animal injury and limiting the parasite's spread, according to Elanco's technical experts Emergency Use Authorization for Elanco's CLiK Extra provides livestock producers with a vital tool in ...

In early August 2026, Elanco Animal Health reported Q2 sales of US$1,368 million and net income of US$54 million, alongside an FDA Emergency Use Authorization for its CLiK Extra screwworm-prevention spray across multiple livestock and wildlife species. The combination of stronger earnings, raised full-year revenue guidance to US$5,090 million–US$5,140 million, and expanded screwworm-related offerings positions Elanco as a key player in responding to a renewed New World screwworm...

Elanco Animal Health Inc (ELAN) delivers robust Q2 2026 results, fueled by blockbuster products Zenrelia and Credelio Quattro, leading to improved profitability and a strengthened balance sheet.

Elanco beat second-quarter estimates, raised 2026 guidance and cited strong Pet Health demand, Zenrelia growth and expanding margins.

Although the revenue and EPS for Elanco Animal Health (ELAN) give a sense of how its business performed in the quarter ended June 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Elanco Animal Health (ELAN) delivered earnings and revenue surprises of +25.93% and +4.41%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Animal health company Elanco (NYSE:ELAN) reported revenue ahead of Wall Street’s expectations in Q2 CY2026, with sales up 10.2% year on year to $1.37 billion. Guidance for next quarter’s revenue was better than expected at $1.21 billion at the midpoint, 1.5% above analysts’ estimates. Its non-GAAP profit of $0.34 per share was 26.5% above analysts’ consensus estimates.

Report highlights Elanco's impact through innovation, expanded access to animal care, a stronger and more sustainable food system and investment in people and communities INDIANAPOLIS, IN / ACCESS Newswire / August 3, 2026 / Elanco Animal Health Incorporated ...

Elanco Animal Health (ELAN) seems "best-positioned name" into the Q2 print, with IDEXX Laboratories

In July 2026, Elanco Animal Health reported peer-reviewed data showing its Credelio Quattro chewable tablets killed black-legged and lone star ticks faster and with more sustained efficacy over 28 days than competing products Simparica Trio and NexGard Plus, while also carrying an FDA-approved claim for Lyme disease prevention in dogs. The unique combination of rapid tick kill within 8 to 12 hours and maintained performance through Day 28 could strengthen Credelio Quattro’s competitive...

Elanco Animal Health stock has delivered a strong 107.8% return over the past three years, yet its current share price of US$24.91 still screens as undervalued when set against an intrinsic value estimate based on a Discounted Cash Flow (DCF) model and broader valuation checks. The 107.8% three year return points to a stock that has already rewarded patient holders, so the main question now is how much upside, if any, remains in the current valuation. Expectations that Elanco Animal Health...

Does Elanco Animal Health Incorporated (ELAN) have what it takes to be a top stock pick for momentum investors? Let's find out.

Elanco Animal Health (ELAN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.